arrow
J

Joost Kluiver

University Medical Center Groningen
H指数:32
被引数:3,808

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Molecular Profiling and Disease Tracking of Post-transplant Lymphoproliferative Disorders using Cell-free DNA

利用游离DNA进行移植后淋巴增生性疾病的分子分型和疾病追踪

2026-08-280
OA
Systematic profiling of AGO2-associated circRNAs and functional investigation reveal circN4BP2L2 as a survival-promoting regulator in T-ALL

AGO2相关环状RNA的系统分析及功能研究揭示circN4BP2L2为T-ALL中的促生存调节因子

Leukemia
IF13.4
2026-07-270
OA
Molecular profiling of cell-free DNA from classic Hodgkin lymphoma patients identifies potential prognostic clusters and corresponds with disease dynamics

经典霍奇金淋巴瘤患者细胞外DNA的分子特征分析鉴定了潜在的预后聚类,并与疾病动态相对应

2025-04-080
OA
Molecular Tumor Board of the University Medical Center Groningen (UMCGMTB): outcome of patients with rare or complex mutational profiles receiving MTB-advised targeted therapy

格罗宁根大学医学中心 (UMCGMTB) 的分子肿瘤委员会: 接受MTB建议的靶向治疗的罕见或复杂突变特征的患者的结果

2024-11-010
OAAI
Core regions in immunoglobulin heavy chain enhancers essential for survival of non-Hodgkin lymphoma cells are identified by a CRISPR interference screen

通过CRISPR干扰筛选鉴定了免疫球蛋白重链增强子中非霍奇金淋巴瘤细胞存活所必需的核心区域

2024-06-270
OAAI
Genomic profiling of post-transplant lymphoproliferative disorders using cell-free DNA
2023-09-144
OAAI
Obituary-Pieter Van Vlierberghe (1980-2022)

Itu告-Pieter Van Vlierberghe (1980-2022)

LEUKEMIA
IF13.4
2023-03-031
OA
Actionability of on-target ALK Resistance Mutations in Patients With Non-Small Cell Lung Cancer: Local Experience and Review of the

非小细胞肺癌患者的靶向ALK耐药突变的可操作性: 本地经验和回顾

2022-03-0120
OAAI